Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2023-06-14 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-06-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the sale of a subsidiary company (TAET Software Co.) by BioVaxys Technology Corp. It details the transaction terms, the company's business focus, and includes forward-looking statements. There is no financial report, audit, earnings data, or regulatory filing content. It is an announcement of a corporate transaction, not a merger or acquisition filing (which would be more formal and detailed), nor a capital financing update. The document is a general corporate announcement about a sale of a business unit, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories.
2023-06-14 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'BIOVAXYS REPORTS AGM RESULTS' and details the results of the Annual General Meeting held on June 6, 2023. It includes voting outcomes on director elections, auditor re-appointment, stock option plan approval, and attendance statistics. It also announces a resignation and interim appointment in senior management. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document is not the full AGM materials or presentations, nor is it an annual report or management discussion. It is a formal announcement of voting results from the AGM. The document length (5834 characters) supports it being a detailed announcement rather than a brief notice. Therefore, the correct classification is DVA with high confidence.
2023-06-07 English
Other.pdf
AGM Information Classification · 100% confidence The document is a Form of Proxy for the Annual and Special Meeting of BioVaxys Technology Corp. It includes instructions for appointing a proxyholder to vote on behalf of shareholders at the AGM, details on voting for directors, appointment of auditors, and approval of a stock option plan. It is clearly related to the Annual General Meeting and contains proxy solicitation materials rather than the actual meeting minutes or presentations. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement or a report publication notice but a proxy form for the AGM.
2023-05-16 English
Management information circular - English.pdf
Regulatory Filings
2023-05-16 English
News release - English.pdf
Regulatory Filings
2023-04-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.